Last reviewed · How we verify
GONADORELIN HYDROCHLORIDE
At a glance
| Generic name | GONADORELIN HYDROCHLORIDE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring (PHASE1, PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Reprometabolic Syndrome Mediates Subfertility in Obesity (NA)
- Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (PHASE2)
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women (EARLY_PHASE1)
- Hormonal Mechanisms of Sleep Restriction - Axis Study (PHASE1)
- Study on Human Bioequivalence of Triprerelin Acetate for Injection (PHASE1)
- GnRH Therapy on Cognition in Down Syndrome (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |